Welcome to our dedicated page for ears news (Ticker: ears), a resource for investors and traders seeking the latest updates and insights on ears stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ears's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ears's position in the market.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced promising preclinical data for its Bentrio™ nasal spray (AM-301), demonstrating its safety and efficacy against SARS-CoV-2. In vitro studies showed a 99% reduction in viral titer upon prophylactic treatment. The spray also reduced viral load 12- to 14-fold when treatment began 24 or 30 hours post-infection. Bentrio™ is set to launch in Germany with plans for wider distribution. This drug-free nasal spray aims to provide personal protection against airborne viruses and allergens.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced the selection of KRAS-driven colorectal cancer as the first indication for its OligoPhore™ platform. The development program, designated AM-401, aims for IND submission by late 2022. With colorectal cancer being the second leading cause of cancer death in the U.S., the company's research highlights a significant unmet medical need. Preclinical studies demonstrated effective KRAS silencing and tumor growth inhibition using OligoPhore™ technology, showcasing its potential in targeted cancer therapeutics.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced its affiliate, Altamira Medica Ltd., will roll out Bentrio™, a drug-free nasal spray against airborne viruses and allergens, starting in Germany. Bentrio™ forms a protective gel layer on the nasal mucosa, reducing the risk of viral infections and alleviating allergy symptoms. In clinical tests, it significantly decreased SARS-CoV-2 infection rates and allergy symptoms. The company also plans to expand distribution in additional countries. Auris Medical will change its name to Altamira Therapeutics Ltd. pending shareholder approval.
Auris Medical Holding Ltd. (NASDAQ: EARS) has reported promising findings from a study using its OligoPhoreTM siRNA technology to combat aggressive Adult T-cell Leukemia Lymphoma (ATLL). The research demonstrated a significant reduction in tumor size and lymphocyte counts, with tumor growth nearly halted. This study, conducted by teams from Washington University and the University of South Florida, highlights effective siRNA delivery and its potential to enhance chemotherapy efficacy. The results suggest substantial implications for ATLL treatment, supported by the urgent need for effective therapies against this aggressive cancer.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced its acquisition of Trasir Therapeutics, a leader in RNA therapeutics. The deal included 0.77 million shares and cash obligations, focusing on Trasir’s OligoPhore™ platform for enhanced oligonucleotide delivery beyond the liver. Dr. Samuel Wickline joins as Chief Scientific Officer. The company plans to pivot towards RNA therapeutics, potentially spinning off existing programs within 12-18 months. An extraordinary meeting will propose a name change to Altamira Therapeutics Ltd. and elect a new board member.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced that its affiliate Altamira Medica is set to conduct a study in India to evaluate its BentrioTM nasal spray's efficacy against airborne viruses and allergens, including Covid-19. The study will begin recruitment in Q3 2021, pending regulatory approvals. Thomas Meyer, CEO, highlighted Bentrio's effectiveness in preliminary studies, emphasizing the ongoing health risks posed by Covid-19 variants. Auris Medical focuses on developing therapeutics in neurotology, rhinology, and allergies, with several product candidates currently in trials.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on June 9, 2021, at 11:00 a.m. EST. This presentation will be webcast live, accessible through the event homepage. Auris Medical, focused on therapeutics for neurotology, rhinology, allergy, and CNS disorders, is developing intranasal betahistine for vertigo treatment and protecting against airborne viruses with its nasal spray Bentrio. The company also has two Phase 3 programs for hearing loss and tinnitus.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced its successful completion of the conformity assessment for its BentrioTM nasal spray, allowing marketing in the EU under the CE mark. The company aims to launch the product by the end of Q2 2021. BentrioTM is a drug-free spray designed to provide protection against airborne allergens and viruses by forming a gel layer in the nasal mucosa. Additionally, Auris Medical plans to submit a 510(k) pre-market notification to the FDA for allergy use in early Q3 2021.
Auris Medical Holding Ltd. (NASDAQ: EARS) announced the completion of midpoint enrollment for Part B of its Phase 2 TRAVERS trial, assessing intranasal AM-125 for acute peripheral vertigo. The trial involves 72 patients recovering from neurosurgery, with the primary efficacy endpoint being the improvement from baseline in the 'Standing on Foam' test at Day 14. An interim analysis showed a positive dose-response relationship, suggesting active treatment effectiveness. The company aims to complete enrollment by Q3 2021, contingent on the pandemic's impact on patient recruitment.
